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Abstract
Aims/hypothesis Diabetic retinopathy is a major complication
of type 2 diabetes and the leading cause of blindness in adults of
working age. Neuronal defects are known to occur early in
disease, but the source of this dysfunction is unknown.
The aim of this study was to examine differences in the
retinal membrane proteome among non-diabetic mice
and mouse models of diabetes either with or without
metformin treatment.
Methods Alterations in the retinal membrane proteome
of 10-week-old diabetic db/db mice, diabetic db/db
mice orally treated with the anti-hyperglycaemic met-
formin, and congenic wild-type littermates were exam-
ined using label-free mass spectrometry. Pathway en-
richment analysis was completed with Genomatix and
Ingenuity. Alterations in Slc17a7 mRNA and vesicular
glutamate transporter 1 (VGLUT1) protein expression
were evaluated using real-time quantitative PCR and
immunofluorescence.
Results A total of 98 proteins were significantly differentially
abundant between db/db and wild-type animals. Pathway
enrichment analysis indicated decreases in levels of proteins
related to synaptic transmission and cell signalling.Metformin
treatment produced 63 differentially abundant proteins com-
pared with untreated db/db mice, of which only 43 proteins
were found to occur in both datasets, suggesting that treatment
only partially normalises the alterations induced by diabetes.
VGLUT1, which is responsible for loading glutamate into
synaptic vesicles, was found to be differentially abundant in
db/db mice and was not normalised by metformin. The de-
crease in Slc17a7 /VGLUT1 was confirmed by transcriptomic
and immunocytochemical analysis.
Conclusions/interpretation These findings expand the knowl-
edge of the protein changes in diabetic retinopathy and sug-
gest that membrane-associated signalling proteins are suscep-
tible to changes that are partially ameliorated by treatment.
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Abbreviations
5NTD 5′-Nucleotidase
ATP2B3 Plasma membrane calcium ATPase 3
CNGA1 Cyclic nucleotide gated channel alpha 1
dbM db/db Mice treated with metformin
GePS Genomatix Pathway System
IPA Ingenuity Pathway Analysis
IPL Inner plexiform layer
LC Liquid chromatography
LC-MS/MS Liquid chromatography tandem mass
spectrometry
MS Mass spectrometry
OPL Outer plexiform layer
OPSB Opsin 1 blue-sensitive
OPSD Opsin 2 rhodopsin
PB Phosphate buffer
RDH12 Retinol dehydrogenase 12
SNG1 Synaptogyrin 1
S38A3 Sodium-coupled neutral amino acid transporter 3
VGLUT1 Vesicular glutamate transporter 1
Introduction
Type 2 diabetes is emerging as a major health issue, with the
global prevalence estimated to reach 300million people by the
year 2025 [1]. This increase has been linked to an ageing
population, lifestyle changes and an increase in global obesity.
At present, the oral anti-hyperglycaemic drug metformin is a
first-line treatment for type 2 diabetes, and predominantly acts
through decreasing glucose production by the liver [2]. In
addition to reducing hyperglycaemia, metformin treatment in
diabetic patients has been linked to decreased rates of
macrovascular disease and mortality [3]. Despite receiving
treatment, however, many diabetic patients are still at in-
creased risk of developing complications associated with the
disease [4, 5].
Diabetic retinopathy is a major complication of types 1
and 2 diabetes [6]. Characterised and diagnosed by altera-
tions in the retinal vasculature [7], studies have shown that
changes to neurons and glia occur during diabetic retino-
pathy [8–10], with functional tests in humans and animal
models indicating that neuronal dysfunction is present
prior to overt vascular damage [11–13]. The underlying
mechanism of neuronal dysfunction is unknown, but con-
nections have been made to abnormal Na/K-ATPase ac-
tivity [14], shortened photoreceptor segments [15] and
differences in the light and dark vs colour visual pathways
[16]. More than 90% of type 1 and 60% of type 2 diabetes
patients develop some form of retinopathy following two
decades of diabetes [6], despite receiving treatment for
hyperglycaemia. This implies that hyperglycaemia-
associated pathological retinal changes are not fully
ameliorated by treatment. As such, it is necessary to un-
derstand the changes in the retina induced by diabetes,
which pathways are affected by disease and the degree to
which treatment ameliorates these alterations.
This study examined the retinal membrane proteome of the
db/db mouse model of type 2 diabetes, and compared it with
the proteome of non-diabetic mice and diabetic mice treated
with metformin (dbM ). Diabetic db/db mice have a mutation
in the Lepr gene (encoding the leptin receptor), resulting in
excessive food consumption and the development of obesity,
hyperglycaemia and insulin resistance [17]. Pathological
changes in the retinas of db/db mice include breakdown of
the blood–retina barrier, acellular capillaries and neuronal
dysfunction [18–20]. The membrane proteome is of particular
interest in understanding changes in the diabetic retina, as it
consists of transporters, receptors and signalling proteins
that might be altered in disease or function as targets of
drug treatment.
Methods
Experimental animals Mice (db/db [BKS.Cg-m+/+Leprdb/db]
and wild-type [BKS.Cg-m+/+Leprm/m]; Jackson Laboratories,
Bar Harbor, ME, USA) were bred and housed in single venti-
lated cages (SealsafePlus AERO IVC Greenline, Tecniplast,
Hohenpeissenberg, Germany) at 22±1°C, with a 12:12 h
light:dark cycle and controlled humidity, in the German Mouse
Clinic, Helmholz Center Munich [21, 22]. All procedures were
performed with approval from the Government of Upper
Bavaria (reference no. 55.2-1-54-2531-70-07) and adhered to
the Principles of Laboratory Animal Care (NIH publication no.
85-23, revised 1985, http://grants1.nih.gov/grants/olaw/
references/phspol.htm).
Male wild-type and db/db mice were fed a high-fat diet
postweaning (S0372-E010, ssniff Spezialdiäten, Soest, Ger-
many). At 8 weeks, mice were fasted for 4 h and weighed, and
blood glucose (Contour, Bayer Vital, Leverkusen, Germany)
and HbA1c (A1cNow
+, Bayer Vital) concentrations were mea-
sured. Inclusion criteria for diabetic mice were weight greater
than 44 g and blood glucose above 19.43 mmol/l. Mice that
met these criteria were matched into two cohorts: one cohort
was treated with metformin (dbM , 300 mg kg−1 day−1; Sigma
Aldrich, Munich, Germany), while the other cohort and wild-
type mice were given placebo (n =10 in each group). Metfor-
min was dissolved in 0.5% placebo solution (95%
hydroxyethylcellulose 250G Pharm, Fagron, Barsbüttel, Ger-
many; 5% Solutol HS15, BASF, Ludwigshafen, Germany)
and applied daily by gavage. At 10 weeks, mice were fasted
for 4 h, weighed, had blood glucose and HbA1c measurements
taken and were killed with an isoflurane overdose 18 h after
treatment. The eyes were enucleated, and retinas were either
dissected, frozen in liquid nitrogen and stored at −80°C until
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further processing, or the anterior chamber was removed and
the posterior eyecup fixed in 4% paraformaldehyde in
0.1 mol/l phosphate buffer (PB; pH 7.4), and processed for
immunofluorescence [23]. Figure 1 shows bodyweight, blood
glucose and HbA1c levels.
Proteomic sample preparation Membrane proteins were
extracted as previously described [24]. Frozen retinal samples
(n =9 per group, in pools of three) were mechanically
homogenised in a high-salt buffer (2 mol/l NaCl; 10 mmol/l
HEPES NaOH, pH 7.4; 1 mmol/l EDTA), lightly centrifuged
(61g , 5 min, 4°C) to remove non-grinded tissue and then
strongly centrifuged (17,500 g , 30 min, 4°C). The remaining
pellet was repeatedly homogenised in a high pH buffer
(0.1 mol/l Na2CO3, pH 11.3; 1 mmol/l EDTA), incubated on
ice and centrifuged (17,500 g , 30 min, 4°C), with the super-
natant fraction removed following each round. Following
homogenisation, membrane protein pellets were solubilised
in 36 μl of 50 mmol/l ammonium bicarbonate and 4 μl 2%
RapiGest (Waters, Milford, MA, USA), reduced with 2 μl of
100 mmol/l dithiothreitol and incubated at 60°C for 10 min.
Samples were alkylated with 2 μl of 300 mmol/l
iodoacetamide at room temperature in the dark and digested
with 4 μl trypsin (0.5mg/ml, Promega, Madison,WI, USA) at
37°C overnight. The reaction was stopped with concentrated
HCl. This was followed by centrifugation, with the soluble
phase collected for liquid chromatography tandem mass spec-
trometry (LC-MS/MS) analysis.
Mass spectrometry LC-MS/MS analysis was performed on an
UltiMate 3000 nano rapid separation LC system (Dionex,
Idstein, Germany) coupled to a linear trap quadrupole Velos
mass spectrometer (Thermo Fisher Scientific, Schwerte, Ger-
many) [25]. Samples were automatically loaded into a HPLC
system (Dionex) at a 6 μl/min flow rate, in 0.5% trifluoracetic
acid in HPLC-grade water onto an Acclaim PepMap100 col-
umn (75 μm inner diameter ×2 cm, C18, 3 μm, 100 Å,
Dionex). After 5 min, peptides were eluted and separated on
an Acclaim PepMap RSLC column (75 μm×25 cm, C18,
2 μm, 100 Å, Dionex) by a linear gradient from 2% to 35%
of buffer B (80% acetonitrile, 0.08% formic acid in HPLC-
grade water) in buffer A (2% acetonitrile, 0.1% formic acid in
HPLC-grade water) at a 300 nl/min flow rate over
150 min. Remaining peptides were eluted by a short
gradient from 35% to 100% buffer B in 5 min. The
eluted peptides were analysed online in the linear trap
quadrupole Velos. From the high-resolution MS prescan
with a mass range from 300 to 1,500 Da, the ten most
intense peptide ions were automatically selected for
fragment analysis in the linear ion trap if they exceeded
an intensity of 200 counts and if they were at least
doubly charged. Target peptides selected for MS/MS
were dynamically excluded for 20 s.
Label-free analysis Acquired spectra (Thermo raw files) were
analysed using Progenesis LC-MS software (Version 4.0,
Nonlinear Dynamics, Newcastle upon Tyne, UK) [24]. The
profile data of the MS scans were transformed into peak lists
with respective intensities, abundances and m/z values.
MS/MS spectra were treated similarly. Using one sample as
the reference, the retention times of the other samples were
manually and automatically aligned to a maximal overlay of
the two-dimensional features. Features with one charge or
more than eight charges were excluded from further analyses.
Samples were then allocated to their respective experimental
groups (wild-type, db/db or dbM).
All MS/MS spectra were exported in Mascot generic for-
mat (mgf) and used for peptide identification with Mascot
(version 2.4; Matrix Science, Boston, MA, USA) using the
Ensembl mouse protein database (www.ensembl.org; Mus
musculus ; release 66 NCBIM37, 56,416 sequences, ftp://ftp.
ensembl.org/pub/current_fasta/mus_musculus/). Search
variables were: 10 ppm peptide mass tolerance; 0.6 Da
MS/MS tolerance; one missed cleavage allowed; methionine
oxidation, asparagine and glutamine deamidation as variable
modifications; and carbamidomethylation as a fixed modifi-
cation. TheMascot-integrated decoy database search calculat-
ed a false discovery rate of less than 1% when searching was













































Fig. 1 (a) Body weight, (b) blood glucose and (c) HbA1c measurements
for wild-type, db/db and dbM mice. db/db and dbM mice had signifi-
cantly increased body weight compared with wild-type mice (wild-type
21.88±0.371 g; db/db 52.36±1.207 g; dbM 51.44±1.013 g; p <0.0001).
Blood glucose was significantly increased in db/db and dbM mice (wild-
type 5.899±0.296 mmol/l; db/db 27.76±0.625 mmol/l; dbM 22.05±
2.009 mmol/l; p <0.0001), as were HbA1c values (wild-type 20.06±
0.400 mmol/mol; db/db 56.57±2.543 mmol/mol; dbM 45.00±
2.400 mmol/mol; p <0.0001). Diabetic db/db and dbM mice had
similar body weight (p >0.999), but dbM mice had significantly
decreased blood glucose (p <0.001) and HbA1c values (p <0.001).
**p <0.001, ****p<0.0001. To convert values for HbA1c in mmol/mol
into%,multiply by 0.09148 and add 2.152, or use the conversion calculator
at www.hba1c.nu/eng/
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performed on the concatenated mgf files with a percolator ion
score cut-off of 15, and the significance threshold p adjusted
to reach the maximum false discovery rate. Identifications
were re-imported into Progenesis. All unique peptides were
included for quantification. Total cumulative protein abun-
dance was calculated by summing the intensities of the indi-
vidual peptides allocated to the respective protein; when two
peptides are identified as belonging to protein X, if the inten-
sity of peptide A is 1,000 and peptide B is 2,000, the total
abundance of protein X is 3,000 [24]. No minimal thresholds
were set for the method of peak picking or selection of data to
use for quantifications. This study used proteins identified and
quantified by at least two peptides for further analysis.
Protein network and pathway enrichment analysis Protein
interaction maps were created by uploading gene identifiers
and fold changes (db /wild-type) for significantly different
proteins into the Genomatix Pathway System (GePS, version
2.3.0, www.genomatix.de, accessed 27 March 2013,
Genomatix, Munich, Germany). Interaction maps were
based on Mus musculus and ‘function word’ as co-citation
level for literature mining. The network was extended by ten
genes via frequent co-citations for Ctbp2 (protein name
RIBEYE), Slc17a7 (vesicular glutamate transporter 1
[VGLUT1]), Ndufa4 (NDUA4). Ndufa9 (NDUA9), Ndufa11
(NDUAB), Ndufa12 (NDUAC), Ndufa13 (NDUAD),
Ndufb6 (NDUB6) and Ndufb10 (NDUBA), and connected
by the shortest path. Candidates without interactions
were removed. Based on db /wild-type fold-change,
upregulated proteins were coloured green and downregulated
proteins were coloured red. Grey colouring represented
network-extended proteins.
Pathway enrichment analyses were performed for down- or
upregulated proteins using Ingenuity Pathway Analysis (IPA;
www.ingenuity.com, accessed 13 December 2012, Ingenuity
Systems, CA, USA). Protein lists were uploaded with
Ensembl mouse accession numbers and core analysis was
performed to identify the biological functions most
significantly represented in the dataset. The analysis used the
Ingenuity Knowledge Base (Ingenuity Systems) as the
reference set, and considered molecules and/or relationships
withMus musculus as the species in experimentally observed
results. p values were calculated using Fisher’s exact test to
determine the probability that a function or disease assigned to
the dataset would occur by chance.
Metformin quantification Retinal metformin levels were deter-
mined using HPLC-MS/MS quantification (unpublished data,
S Zukunft, C Muschet, J Adamski). Frozen retinal samples of
placebo- and metformin-treated db/db mice were transferred
into dry-ice-cooled 1.4 mm Precellys tubes (Peqlab
Biotechnologie, Erlangen, Germany) and homogenised in
HPLC-grade methanol (20 μl/mg tissue; AppliChem,
Darmstadt, Germany). The homogenates were diluted 1:100
in HPLC-grade methanol containing 5 ng/ml deuterium-
labelled metformin (metformin-d6), which served as an internal
standard. MS/MS measurements were performed on a QTRAP
5500 System (AB Sciex, Darmstadt, Germany) coupled to an
1260 Infinity Series HPLC (Agilent, Böblingen, Germany) and
an HTC-xt PAL autosampler (CTC Analytics, Zwingen, Swit-
zerland), controlled by Analyst 1.6.1 software (AB Sciex).
Reverse-phase LC was performed applying a methanolic
isocratic mobile phase. Metformin was identified by
multiple reaction monitoring using 130.04/60.00 Da as
Q1/Q3 mass pairs for metformin and 136.09/60.00 Da
for metformin-d6. Quantification was assessed by comparing
sample peak areas with those of a methanol-dissolved
metformin standard curve.
Relative qRT-PCR quantification Total RNA was isolated
from wild-type and db/db retinas (n =3 per group) [26].
Samples were homogenised in 750 μl TRIzol (Invitrogen,
Karlsruhe, Germany) and incubated for 5 min. Chloroform
(150 μl) was added, followed by incubation for 3 min and
centrifuged (17,500 g , 15 min, 4°C). The supernatant fraction
was transferred to a new tube with 375 μl isopropanol, incu-
bated for 10min and centrifuged (17,500 g , 10min, 4°C). The
pellet was washed with 75% ethanol and treated with the RQ1
RNase-Free DNase kit (Promega) to eliminate contaminating
genomic DNA. Total RNAwas quantified using a NanoDrop
photometer (Thermo Fisher Scientific) and cDNA generated
using the Fermentas RevertAid First Strand cDNA Synthesis
Kit (Thermo Fisher Scientific) following the manufacturer’s
instructions. To improve the yield, oligo(dT)20-primers and
random hexamer primers were used for synthesis. Slc17a7
gene expression was assessed relative to the Hprt1 house-
keeping gene (primer sequences in Electronic Supplementary
Material [ESM] Table 1). Real-time PCR was performed
using a LightCycler 480 (Roche Diagnostics, Mannheim,
Germany) using the KAPA SYBR FAST qPCR MasterMix
for Roche LightCycler 480 Kit (Peqlab Biotechnologie).
Immunofluorescence and photography VGLUT1 expression
was examined with immunofluorescence (n =6) [23]. Vertical
cryosections of 12 μm were blocked with 10% normal goat
serum, 1% BSA and 0.5% Triton-X 100 in PB for 1 h, and
incubated in anti-VGLUT1 antibody (AB#5905, Millipore,
Schwabach, Germany) diluted 1:5,000 in buffer (3% normal
goat serum, 1%BSA and 0.5% Triton-X 100 in PB) overnight
at room temperature. After rinsing, sections were incubated
with goat anti-guinea pig Alexa Fluor 488 secondary antibody
(Invitrogen) diluted 1:1,000 in buffer for 90 min, washed in
PB and coverslipped. All sections were photographed with
constant variables on an AxioImager Z1 with ApoTome at-
tachment (Zeiss, Göttingen, Germany). Mean intensities of
VGLUT1 labelling in the outer plexiform layer (OPL) and
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inner plexiform layer (IPL) were measured using the Defini-
ens Enterprise Image Intelligence Suite (Definiens, Munich,
Germany).
Statistical analysis All values are expressed as mean ± SEM.
Body weight, blood glucose and HbA1c were analysed with
one-way ANOVA and Bonferroni post hoc test using an alpha
of 0.05. All other data were analysed using Student’s t test.
Results were considered significant at p <0.05.
Results
Identification of proteins and protein networks in diabetic
retina A total of 844 proteins were identified in the
membrane-enriched fractions of retinal tissue from wild-
type, db/db and dbM mice, of which 513 proteins were
identified and quantified by more than one peptide and used
for further analysis (ESM Tables 2 and 3). Analysis of the
subcellular location of the identified proteins was completed
using the UniProtKB/Swiss-Prot database. Overall, 64% of
identified proteins were annotated with ‘membrane’ or varia-
tions thereof (ESM Fig. 1), which is comparable with other
membrane proteome studies [24].
A total of 98 proteins were differentially abundant (p <0.05)
between wild-type and db/db retinas, of which 80 were
downregulated and 18 upregulated (ESM Table 4). A protein
interaction network map was generated using GePS to identify
functional clusters affected by diabetes (Fig. 2). Nine candidates
were chosen to extend the network: Ndufa4 , Ndufa9 , Ndufa11 ,
Ndufa12 , Ndufa13 , Ndufb6 and Ndufb10 , which are subunits
of NADH dehydrogenase (ubiquinone) I, also known as com-
plex I, from the electron transport chain; and Ctbp2 (RIBEYE)
and Slc17a7 (VGLUT1), which are known to have important
roles in retinal synaptic transmission. Extending by the most
frequently co-cited genes and then removing results without
connections produced a loosely interconnected network of 41
proteins from the dataset, with 12 additional proteins. Two
proteins added to the network formed many connections with
other proteins from the dataset and with other added proteins:
Ins2 , the mouse orthologue of insulin (INS), and Trp53 , the
mouse orthologue of tumour protein 53 (TP53).
Pathway enrichment analysis with IPA was completed to
determine the biological processes most affected in diabetic
retinas. The 80 proteins with decreased abundances in diabe-
tes were significantly associated with 367 biological functions
(ESMTable 5). Table 1 lists the top fivemolecular and cellular
functions. Cell-to-cell signalling was the highest ranking cat-
egory with 11 annotated functions, of which synaptic trans-
mission was the most significantly annotated (p =7.93×10−6).
The synaptic transmission annotation contained eight pro-
teins, which included several proteins identified in the GePS
protein interaction network. Other highly ranking categories
include molecular transport and amino acid metabolism. IPA
identified 210 significantly enriched biological functions as-
sociated with the 18 upregulated proteins (ESM Table 6). Cell
death and survival was the highest ranking molecular func-
tion, with four proteins and four functions (Table 2), of which
recovery of retinal rods was the most significantly annotated
function (p =1.17×10−6). These biological functions were not
enriched when the entire set of 513 detected and quantified
proteins underwent pathway analysis (ESM Table 7).
Effect of metformin on diabetic retinas In order to confirm that
metformin crossed the blood–retinal barrier, a direct measure-






























Fig. 2 Interaction map of differentially abundant retinal proteins in
diabetes. A total networkwas generated with GePS using functional word
as connector. Proteins abbreviations are based on official gene symbols
(NCBI Entrez Gene). Upregulated proteins are presented in green,
downregulated proteins in red and network-extended proteins in grey.
The network indicates a moderate degree of functional interaction among
proteins affected by diabetes
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Table 1 Top five molecular and cellular functions associated with proteins downregulated in diabetic retinas
Category and annotations p value Molecules No. molecules
Cell-to-cell signalling and interaction
Synaptic transmission 7.93×10−6 DPP6, GLRB, SLC12A5, SLC17A7, SLC1A3,
SV2A, SV2B, VDAC1
8
Long-term potentiation 4.10×10−3 DPP6, KRAS, SLC17A7, SYNGR1, VDAC1 5
Long-term potentiation of synapse 4.59×10−3 DPP6, SLC17A7, SYNGR1, VDAC1 4
Accumulation of 5-hydroxytryptamine 4.81×10−3 MAOA 1
Sequestration of neurotransmitter 4.81×10−3 SLC17A7 1
Release of L-glutamic acid 6.87×10−3 SLC17A7, SLC1A3 2
Paired-pulse facilitation of synapse 1.81×10−2 SYNGR1, VDAC1 2
Aggregation of neurons 2.38×10−2 ATP1B1 1
Catabolism of dopamine 2.38×10−2 MAOA 1
Plasticity of synapse 4.23×10−2 KRAS, SYNGR1 2
Formation of adherens junctions 4.25×10−2 KRAS 1
Cellular assembly and organisation
Activation of permeability transition pores 2.28×10−5 SLC25A4, SLC25A5 2
Fragmentation of microtubules 4.81×10−3 TUBB 1
Organisation of axon terminals 4.81×10−3 MAOA 1
Expansion of thalamocortical axons 9.59×10−3 MAOA 1
Quantity of thalamocortical axons 9.59×10−3 MAOA 1
Segregation of sensory projections 9.59×10−3 MAOA 1
Morphology of Golgi apparatus 1.44×10−2 TMED10 1
Organisation of Golgi apparatus 2.85×10−2 TMED10 1
Formation of adherens junctions 4.25×10−2 KRAS 1
Morphology of mitochondria 4.35×10−2 NDUFA13, SLC25A4 2
Amino acid metabolism
Import of L-glutamic acid 6.81×10−5 SLC17A7, SLC1A3 2
Synthesis of GABA 4.81×10−3 SLC1A3 1
Synthesis of L-glutamic acid 4.81×10−3 SLC1A3 1
Release of L-glutamic acid 6.87×10−3 SLC17A7, SLC1A3 2
Metabolism of L-glutamic acid 1.91×10−2 SLC1A3 1
Molecular transport
Import of L-glutamic acid 6.81×10−5 SLC17A7, SLC1A3 2
Transport of anions 1.39×10−4 GLRB, SLC12A5, SLC4A3, VDAC1 4
Transport of ions 5.13×10−4 ATP2B1, CAMK2D, CAMK2G, GLRB,
SLC12A5, SLC4A3, VDAC1
7
Transport of molecules 1.51×10−3 ATP2B1, CAMK2D, CAMK2G, GLRB,
SLC12A5, SLC17A7, SLC1A3, SLC4A3,
TMED10, VDAC1
10
Transport of Ca2+ 3.14×10−3 ATP2B1, CAMK2D, CAMK2G 3
Accumulation of 5-hydroxytryptamine 4.81×10−3 MAOA 1
Exchange of ADP 4.81×10−3 SLC25A4 1
Exchange of ATP 4.81×10−3 SLC25A4 1
Release of lactic acid 4.81×10−3 SLC1A3 1
Translocation of ADP 4.81×10−3 VDAC1 1
Release of L-glutamic acid 6.87×10−3 SLC17A7, SLC1A3 2
Transport of chloride 6.87×10−3 GLRB, SLC12A5 2
Redistribution of cholesterol 1.91×10−2 ATP1A1 1
Transport of cations 2.47×10−2 ATP2B1, CAMK2D, CAMK2G, SLC12A5 4
Small-molecule biochemistry
Import of L-glutamic acid 6.81×10−5 SLC17A7, SLC1A3 2
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4 h drug-treated db/db mice. A total of 8.52 ±
1.28 nmol/g of metformin was detected in retinas from
drug-treated mice, while none was detected in the
placebo-treated group.
Retinal membrane proteins from metformin-treated db/db
mice were analysed to examine whether drug treatment
ameliorated diabetes-induced changes. A total of 63
proteins were differentially abundant between the
Table 1 (continued)
Category and annotations p value Molecules No. molecules
Accumulation of 5-hydroxytryptamine 4.81×10−3 MAOA 1
Exchange of ADP 4.81×10−3 SLC25A4 1
Exchange of ATP 4.81×10−3 SLC25A4 1
Oxidation of lactic acid 4.81×10−3 MLXIPL 1
Release of lactic acid 4.81×10−3 SLC1A3 1
Sequestration of neurotransmitters 4.81×10−3 SLC17A7 1
Synthesis of GABA 4.81×10−3 SLC1A3 1
Synthesis of L-glutamic acid 4.81×10−3 SLC1A3 1
Translocation of ADP 4.81×10−3 VDAC1 1
Release of L-glutamic acid 6.87×10−3 SLC17A7, SLC1A3 2
Metabolism of L-glutamic acid 1.91×10−2 SLC1A3 1
Redistribution of cholesterol 1.91×10−2 ATP1A1 1
Catabolism of dopamine 2.38×10−2 MAOA 1
Synthesis of glucocorticoids 2.85×10−2 ATP1A1 1
Protein abbreviations are based on official gene symbols (NCBI Entrez Gene)
Table 2 Top five molecular and cellular functions associated with proteins upregulated in diabetic retina
Category and annotations p value Molecules No. molecules
Cell death and survival
Recovery of retinal rods 1.17×10−6 ABCA4, RGS9BP 2
Delay in recovery of retinal rods 1.11×10−3 ABCA4 1
Apoptosis of endothelial cell lines 4.45×10−3 CDH2 1
Apoptosis of photoreceptors 1.22×10−3 ROM1 1
Cellular compromise
Degeneration of photoreceptors 1.07×10−3 ABCA4, ROM1 2
Neurodegeneration of photoreceptors 6.67×10−3 ROM1 1
Degeneration of retinal rods 1.33×10−2 ROM1 1
Amino acid metabolism
Transport of L-histidine 1.11×10−3 SLC38A3 1
Transport of L-glutamine 2.23×10−3 SLC38A3 1
Carbohydrate metabolism
Quantity of N-retinylidene-phosphatidylethanolamine 1.11×10−3 ABCA4 1
Cell morphology
Size of rod outer segment disks 1.11×10−3 ROM1 1
Abnormal morphology of photoreceptor outer segments 1.12×10−3 ABCA4, ROM1 2
Blebbing of nucleus 2.23×10−3 LMNB1 1
Length of rod outer segments 4.45×10−3 ROM1 1
Abnormal morphology of rod outer segments 1.55×10−2 ROM1 1
Innervation of muscle 2.43×10−2 LMNB1 1
Abnormal morphology of photoreceptors 3.73×10−2 ABCA4 1
Extension of axons 4.16×10−2 CDH2 1
Protein abbreviations are based on official gene symbols (NCBI Entrez Gene)
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db/db and dbM samples (p<0.05, ESM Table 8). Combin-
ing these results with the analysis of wild-type vs db/db
samples, 43 of the identified proteins occurred in both datasets
(Fig. 3); 55 were not significantly altered, and a further 20
proteins were not detected in the wild-type vs db/db dataset.
Six of the 43 normalised proteins were complex I subunits:
NDUA4, NDUA9, NDUAC, NDUAD, NDUB6 and
NDUBA. The abundance of these proteins was similar in
wild-type and dbM mice, indicating normalisation through
metformin treatment (Fig. 4). Of the 55 proteins from the
wild-type vs db/db dataset that did not exhibit a significant
change following metformin treatment, some protein abun-
dances e.g. VGLUT1, synaptogyrin 1 (SNG1) and sodium-
coupled neutral amino acid transporter 3 (S38A3) were differ-
ent fromwild-type levels following treatment (Fig. 5a–c), while
others e.g. opsin 1 blue -sensitive (OPSB), NDUAB and plas-
ma membrane calcium ATPase (ATP2B3) showed large varia-
tions in sample protein levels (Fig. 5d–f). However, protein
abundances demonstrated a trend towards normalisation. Some
of the 20 proteins significantly altered in db/db vs dbM mice,
but not in wild-type vs db/db mice, could have resulted from
variations in sample abundance (Fig. 6a, b). Nevertheless,
abundances of other proteins e.g. opsin 2 rhodopsin
(OPSD), retinol dehydrogenase 12 (RDH12), cyclic nu-
cleotide gated channel alpha 1 (CNGA1) and 5′-nucle-
otidase (5NTD) were dramatically altered following
metformin treatment (Fig. 6c–f).
Slc17a7/VGLUT1 alterations in diabetic retinas VGLUT1,
encoded by Slc17a7 , was selected for validation because it
was differentially abundant between wild-type and db/db
samples, not altered by metformin treatment and identified
by GePS and IPA as having significant protein connections
and functions. Using quantitative PCR, gene expression of
Slc17a7 in diabetic retinas was found to be 41% of wild-type
expression (Fig. 7). Because VGLUT1 is expressed at the
glutamatergic synapses of photoreceptors and bipolar cells in
the OPL and IPL [27], immunofluorescence was used to
determine if VGLUT1 downregulation occurred in a specific
location. Strong punctate labelling with VGLUT1 antibody
was observed in the OPL and IPL in wild-type animals
(Fig. 8a). In comparison, expression of VGLUT1 appeared
to be decreased in both corresponding layers of the db/db
retina (Fig. 8b). Quantification of VGLUT1 immunoreactivity
found a significant decrease in db/db mice in the OPL
(p <0.01, Fig. 8c) and an even greater reduction in the IPL,
compared with wild-type (p <0.001, Fig. 8d). Taken together,
these data indicate decreases in retinal VGLUT1 protein and
gene expression, and anatomic localisation in diabetes.
Discussion
We used label-free quantitative MS to examine the retinal
membrane proteome at an early stage of diabetes. We identi-
fied pathways most affected by disease and investigated the
effect of metformin on the membrane proteome of the diabetic
retina. Our study revealed 98 differentially abundant proteins
between wild-type and diabetic mice. Bioinformatics analysis
indicated that these proteins were associated with cell signal-
ling, particularly synaptic transmission. A total of 63 differ-
entially abundant retinal membrane proteins were detected in
Fig. 3 Venn diagram showing the number of proteins identified in retinas
from wild-type vs db/db (dark grey) and db/db vs dbM (light grey) mice.
A total of 98 proteins were identified as being differentially abundant in
diabetic vs non-diabetic mice. Metformin treatment produced 63 differ-
entially abundant proteins from untreated diabetic mice. A total of 43
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Fig. 4 Complex I proteins normalised by metformin treatment as mea-
sured by MS. NDUA4 (a), NDUA9 (b), NDUAC (c), NDUAD (d) and
NDUB6 (e) abundances were significantly decreased in db/db mice
compared with wild-type and dbM mice, while NDUBA (f) was in-
creased. Levels of these proteins were comparable in dbM and wild-type
mice. *p <0.05. Protein abundances are arbitrary units
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diabetic mice treated with metformin compared with untreated
diabetic retinas. Of these, 43 were found to overlap with the
wild-type vs diabetes dataset, leaving 55 proteins not
significantly affected by metformin treatment. Finally,
qPCR and immunofluorescence analyses indicated a signifi-
cant decrease in VGLUT1 protein and gene expression levels
in the diabetic retina.
Proteomic studies of diabetes and diabetic complications
can provide valuable information on the pathogenesis of the
disease by identifying and quantifying biomarkers. The earli-
est proteomic diabetic retinopathy studies were conducted in
2007. Comparing healthy and diabetic rat retinas, two-
dimensional electrophoresis was used to separate proteins,
which were subsequently identified using matrix-assisted la-
ser desorption/ionisation time of flight (MALDI-TOF) and
MS/MS. Alterations in a number of proteins, including succi-
nyl CoA ligase, phosducin, glutamine synthetase and αA-
crystallin, were described [28, 29]. Later studies identified
upregulation of α-, β-, and γ-crystallin isoforms, but reported
conflicting results as to whether insulin treatment normalised
these alterations [30, 31]. The identification of changes to
crystallin isoforms is notable as these proteins belong to the
heat-shock protein family and are involved in apoptosis reg-
ulation and vascular remodelling [32, 33]. Despite these prom-
ising results, relatively few proteomic studies have since been
conducted on the diabetic vitreous or retina [28–31, 34–38],
and none has concentrated specifically on the membrane
proteome.
We have focused on the membrane proteome for a number
of reasons. Membrane-bound proteins include signal trans-
ducers, transporters and receptors, which are likely to be
among the first proteins affected by systemic hyperglycaemia
and, being on the cell surface, are possible therapeutic targets.
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Fig. 5 Selected non-significantly different proteins between db/db and
dbM treatment groups, as measured by MS. While all of the proteins
presented were significantly altered from wild-type levels, they were not
significantly affected (p>0.05) by metformin treatment. (a) VGLUT1, (b)
SNG1, (c) S38A3, (d) OPSB, (e) NDUAB and (f) ATP2B3 protein























Fig. 7 Changes in Slc17a7 gene expression in a mouse model of
diabetes. The mRNA level of Slc17a7 was decreased in diabetic retinas
(db/db ) compared with non-diabetic wild-type animals. Data are
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Fig. 6 Selected significantly different proteins between db/db and dbM
treatment groups. Mass spectrometricmeasurements showed variations in
the individual wild-type sample abundances of (a) monocarboxylate
transporter 1(MOT1) and (b) signal-regulatory protein alpha (SIRPA),
demonstrating that some proteins may not have been identified as signif-
icantly altered between wild-type and db/db measurements. However,
metformin treatment did change the abundances of non-altered proteins,
such as (c) OPSD, (d) RDH12, (e) CNGA1 and (f) 5NTD. *p<0.05.
Protein abundances are arbitrary units
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on the relatively low abundance of membrane proteins com-
pared with cytosolic proteins in their results [34], but improve-
ments in sample preparation methods have now made it
possible to analyse this specific subset of proteins [24]. Final-
ly, immunohistochemical studies examining retinas from oth-
er diabetic animal models have reported defects in cell mem-
brane proteins such as occludin [39], connexin-26 [23] and
connexin-43 [40]. These proteins were not differentially abun-
dant in our study; however, a number of proteins in our dataset
were associated with cell signalling, particularly in synaptic
transmission.
Decreased abundances of synaptic proteins may have rel-
evance regarding the neuronal dysfunction observed in dia-
betic retinopathy. A number of electroretinogram studies in
humans and animal models have reported decreases in inner
retinal waveform components [12, 23, 41], indicating that
postreceptoral neurons are particularly susceptible in diabetic
retinopathy. The cause of these defects is unknown, but the
downregulation of synaptic transmission proteins may indi-
cate alterations in the steps required to transmit synaptic
signals. VGLUT1 is the major transporter responsible for
loading the excitatory neurotransmitter glutamate into synap-
tic vesicles, and is expressed at ribbon synapses in photore-
ceptors in the OPL and ‘ON’ bipolar cells in the IPL [27]. In
our study, VGLUT1 was decreased in the diabetic retina at the
mRNA and protein levels, and was not normalised by metfor-
min treatment. As the electroretinogram is a serial waveform
corresponding to the activity of different neuronal populations
[42], a decrease in VGLUT1 might result in altered rates and
amounts of glutamate loading, affecting the magnitude of
signal transmission from photoreceptors to bipolar cells and
between postreceptoral neurons.
While metformin has been detected in the central nervous
system [43], this is the first study to demonstrate its presence
in the retina. Metformin was detected at comparable levels
with those found in different brain regions of metformin-
treated rats [43], indicating that retinal alterations following
drug treatment could be caused by a direct effect.We observed
the downregulation of complex I subunits in the db/db retina
and subsequent normalisation by metformin. Decreases in the
ratio of free cytosolic NAD+ to NADH in diabetic retinas have
been linked to altered aldose reductase activity [44, 45];
however, as complex I catalyses the transfer of electrons from
NADH to coenzyme Q, reduced abundance of complex I
subunits could lessen the dehydrogenase ability, resulting in
increased free NADH. In contrast to our results, previous
work using rat livers found that metformin directly inhibited
complex I [46]. The difference in metformin response be-
tween these studies could be attributed to experimental design.
First, the rats received metformin for 5 days, and were then
culled 4 h after treatment [46]; animals in our study were
treated for 14 days and culled 18 h later. Therefore, we
primarily investigated effects caused by subchronic metfor-
min treatment. Second, disparities in our studies could be due
to differences between liver and retinal tissue. That metformin
may have varied effects in diverse tissues over time is sup-
ported by a recent study in which skeletal muscle samples
from type 2 diabetic patients, who had taken their last dose of
metformin 12 h before biopsy collection, were found to have
normal complex I function [47]. Nonetheless, the effect of
metformin within the retina should be examined further.
That metformin treatment did not reverse all diabetic alter-
ations was not unexpected. Previous studies have found that
chronic insulin treatment only partially normalised changes in
the retinal proteome and transcriptome [31, 48]. In addition,
because HbA1c and glycaemic levels were not fully
normalised with metformin in this study, longer and/or more
vigorous treatment may produce additional differences in
retinal proteins. Although glycaemic regulation substantially
decreases the risk of developing diabetic complications, the
reduction of ophthalmic complications is closely linked to
hypertension control, particularly via the renin–angiotensin
system [49, 50]. A study examining the effect of
angiotensin-1 receptor antagonism on the whole retinal prote-
ome of diabetic mice found that 72% of the proteins altered in
diabetes were normalised by treatment, and that these were
associated with metabolic and apoptotic abnormalities [34].
The authors did not report whether their animals also received
treatment for hyperglycaemia. It would therefore be interest-
ing to examine how the combination of anti-hyperglycaemic
and anti-hypertensive treatment affects the diabetic retinal
proteome.
Fig. 8 Altered retinal VGLUT1 immunoreactivity in diabetes. Retinas
from (a) wild-type and (b) diabetic mice were assessed for VGLUT1
immunolabelling. The intensity of VGLUT1 labelling was assessed in (c)
the OPL and (d) the IPL. In wild-type retinas, VGLUT1 labelling was
strongly present in the OPL with punctate labelling in the IPL. The
intensity of VGLUT1 labelling appeared decreased in diabetic retinas in
both layers. Quantification of fluorescence intensity indicated significant
decreases in both the OPL (**p <0.01) and the IPL (***p <0.001). Scale
bar: 50 μm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL,
outer nuclear layer
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In summary, we identified 98 differentially abundant retinal
membrane proteins in a mouse model of type 2 diabetes using
label-free MS. Network and pathway enrichment analysis
indicated defects in proteins involved with electron transport
and cell signalling. Metformin treatment partially normalised
these changes. Our findings may have relevance to the neuro-
nal dysfunction observed in diabetic retinopathy.
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